Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs
26 August 2019 - 8:30PM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with open-angle glaucoma, retinal diseases and other
diseases of the eye today announced the appointment of Luis Vargas,
M.D., as Medical Director, Medical Affairs, reporting to Welyn Bui,
PharmD, Aerie’s Vice President of Medical Affairs. Dr. Vargas will
oversee the organizational planning and operational needs of
medical affairs at Aerie. He most recently held related positions
at Revision Optics and Abbott Laboratories.
In connection with his acceptance of the position as Medical
Director, Medical Affairs, Dr. Vargas will receive awards totaling
14,400 stock options that will vest over 4 years, with 25% vesting
on the first anniversary of the hire date and the remainder vesting
ratably on each of the subsequent 36 monthly anniversaries of the
hire date. This award was made outside of Aerie’s
stockholder-approved equity incentive plan and was approved by the
Company’s independent directors as an inducement material to Dr.
Vargas entering into employment with the Company in reliance on
NASDAQ Listing Rule 5635(c)(4), which requires this public
announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with open-angle glaucoma,
retinal diseases and other diseases of the eye. Aerie's first
product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a
once-daily eye drop approved by the U.S. Food and Drug
Administration (FDA) for the reduction of elevated intraocular
pressure (IOP) in patients with open-angle glaucoma or ocular
hypertension, was launched in the United States in April 2018. In
clinical trials of Rhopressa®, the most common adverse reactions
were conjunctival hyperemia, corneal verticillata, instillation
site pain, and conjunctival hemorrhage. More information about
Rhopressa®, including the product label, is available at
www.rhopressa.com. Aerie’s second product for the reduction of
elevated intraocular pressure in patients with open-angle glaucoma
or ocular hypertension, Rocklatan® (netarsudil and latanoprost
ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose
combination of Rhopressa® and the widely-prescribed PGA
(prostaglandin analog) latanoprost, has been approved by the FDA
and is now available in the United States. In clinical trials of
Rocklatan®, the most common adverse reactions were conjunctival
hyperemia, corneal verticillata, instillation site pain, and
conjunctival hemorrhage. More information about Rocklatan®,
including the product label, is available at www.rocklatan.com.
Aerie continues to focus on global expansion and the development of
additional product candidates and technologies in ophthalmology,
including for wet age-related macular degeneration and diabetic
macular edema. More information is available at
www.aeriepharma.com.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: our expectations
regarding the commercialization and manufacturing of Rhopressa® and
Rocklatan® or any future product candidates, including the timing,
cost or other aspects of the commercial launch of Rhopressa® and
Rocklatan® or any future product candidates; our commercialization,
marketing, manufacturing and supply management capabilities and
strategies; the success, timing and cost of our ongoing and
anticipated preclinical studies and clinical trials for Rhopressa®
and Rocklatan®, with respect to regulatory approval outside of the
United States or additional indications, and any future product
candidates, including statements regarding the timing of initiation
and completion of the studies and trials; our expectations
regarding the effectiveness of Rhopressa®, Rocklatan® or any future
product candidates; the timing of and our ability to request,
obtain and maintain FDA or other regulatory authority approval of,
or other action with respect to, as applicable, Rhopressa®,
Rocklatan® or any future product candidates, including the expected
timing of, and timing of regulatory and/or other review of, filings
for, as applicable, Rhopressa®, Rocklatan® or any future product
candidates; the potential advantages of Rhopressa® and Rocklatan®
or any future product candidates; our plans to pursue development
of additional product candidates and technologies within and beyond
ophthalmology; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma, including development of our
retina program; our ability to protect our proprietary technology
and enforce our intellectual property rights; and our expectations
regarding strategic operations, including our ability to in-license
or acquire additional ophthalmic products, product candidates or
technologies. By their nature, forward-looking statements involve
risks and uncertainties because they relate to events, competitive
dynamics, industry change and other factors beyond our control, and
depend on regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). In particular, FDA approval of
Rhopressa® and Rocklatan® do not constitute FDA approval of
AR-1105, AR-13503 or any future product candidates, and there can
be no assurance that we will receive FDA approval for AR-1105,
AR-13503 or any future product candidates. FDA approval of
Rhopressa® and Rocklatan® also do not constitute regulatory
approval of Rhopressa® and Rocklatan® in jurisdictions outside the
United States and there can be no assurance that we will receive
regulatory approval for Rhopressa® and Rocklatan® in jurisdictions
outside the United States. In addition, the acceptance of the INDs
by the FDA for AR-1105 and AR-13503 does not constitute FDA
approval of AR-1105 or AR-13503 and the outcome of later clinical
trials for AR-1105 or AR-13503 may not be sufficient to submit an
NDA with the FDA or to receive FDA approval. Forward-looking
statements are not guarantees of future performance and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190826005005/en/
Media: Tad Heitmann 949-526-8747; theitmann@aeriepharma.com
Investors: Ami Bavishi 908-947-3949; abavishi@aeriepharma.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Apr 2024 to May 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From May 2023 to May 2024